Shots:
- PDS Biotech reported the final topline results from the P-II (VERSATILE-002) Study evaluating safety and efficacy of PDS0101 (Versamune HPV) + Keytruda in 1L R/M HPV16+ HNSCC (n=53)
- In the Study PDS0101 (SC) with pembrolizumab (IV) for the first 4 cycles, then as a final single dose on cycle 12. Pembrolizumab monotx. was given on alternating cycles until cycle 35, until disease progression, or death. The mOS in pts with CPS ≥ 1 was 39.3mos. and the lower limit of the 95% confidence interval is 23.9mos. and the upper limit is not yet estimable
- Treatment was well tolerated, with no discontinuations; PDS is advancing the VERSATILE-003 P-III study in HPV16+ HNSCC population
Ref: PDS Biotech | Image: PDS Biotech | Press Release
Related News:- argenx Reports Topline P-III (ADAPT SERON) Trial Data of Vyvgart for AChR-Ab Seronegative Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
